Enanta Pharmaceuticals (ENTA) Cash from Financing Activities (2012 - 2026)

Enanta Pharmaceuticals has reported Cash from Financing Activities for 15 years, with the latest figure at -$7.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 5.92% year-over-year to -$7.3 million; the trailing twelve-month figure through Mar 2026 stood at $42.1 million (up 263.57% YoY), and the FY2025 full-year result was -$26.6 million, up 3.65% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$7.3 million, down from $64.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $199.9 million in Q2 2023, with the low at -$8.3 million in Q3 2025.
• Historically, Cash from Financing Activities has averaged $12.4 million across 5 years, with a median of -$5.0 million in 2024.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 4751.33% — and 2024, when it tumbled 31269.57%.
• Enanta Pharmaceuticals' Cash from Financing Activities stood at $301000.0 in 2022, then tumbled by 2541.86% to -$7.4 million in 2023, then jumped by 32.16% to -$5.0 million in 2024, then soared by 1386.32% to $64.1 million in 2025, then tumbled by 111.37% to -$7.3 million in 2026.
• The last three Cash from Financing Activities figures came in at -$7.3 million (Q1 2026), $64.1 million (Q4 2025), and -$8.3 million (Q3 2025), per Business Quant data.